Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Souza, W. Teodoro, S. Carrasco, R. Kairalla, C. Borges, C. Goldenstein-Schainberg, E. Parra, E. Carvalho, E. Bonfa, N. Yoshinari, V. Capelozzi (Sao Paulo, Brazil). Abnormal collagen type V deposition in lung fibroblast is correlated with a worse pulmonary function in systemic sclerosis. Eur Respir J 2007; 30: Suppl. 51, 543

Member's Comments

No comment yet.

Related content which might interest you: Collagen V nasal tolerance promotes decrease in topoisomerase-1 and pulmonary fibrosis of systemic sclerosis model Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Type V collagen nasal tolerance regulates collagen mRNA synthesis in pulmonary remodeling of experimental systemic sclerosis Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Collagen V and decorin is involved in systemic sclerosis pulmonary fibrosis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 Increased mRNA expression of collagen V gene in pulmonary fibrosis of systemic sclerosis Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Pulmonary interstitium remodeling by collagen V is associated with profibrotic cytocines in experimental systemic sclerosis Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Refractory remodeling of intrapulmonary arteries by type V collagen, apoptosis and endothelial activation in experimental systemic sclerosis Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Expression of hyaluronidase by interstitial myofibroblasts and epithelial cells is associated with fibrosis extension, clinical forms and pulmonary function stage in patients with systemic sclerosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Collagen V nasal tolerance reverts pulmonary immune cells proliferation and interstitium remodeling in experimental scleroderma Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Up-regulation of collagen type V mRNA in a model of systemic sclerosis Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Systemic sclerosis patients‘ sera recognize collagen V in experimental scleroderma lung fibrosis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 Arterial type V collagen disorganization in patients with systemic sclerosis: preliminary study Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1393-1402 Year: 2015 Tridimensional reconstruction and biochemical profile of collagen V alpha-2 chain in lung fibroblasts culture from patients with systemic sclerosis indicate a defect in fibrillogenesis microarchitecture Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Late stage of experimental pulmonary fibrosis is modulated by collagen V Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Pentastatin, matrikine of the type IV collagen a5 drives pulmonary hypertension via endothelial dysfunction Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The change of lung diffusion capacity does not influence the prognosis in patients with pulmonary arterial hypertension associated with systemic sclerosis. Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Treg alterations lead to systemic and local immune deregulation in idiopathic pulmonary fibrosis and collagen vascular disease-associated interstitial pneumonia Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFβ1-induced fibroblast differentiation into myofibroblasts Source: Annual Congress 2009 - From emphysema to fibrosis: mechanisms of cellular remodelling in the diseased lung Year: 2009